Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease. Its specialty portfolio is best known for Copaxone (glatiramer acetate), a long‑standing therapy for multiple sclerosis, while the broader business includes complex generics, emerging biosimilars, innovative formulations and pipeline programs. The company also offers contract manufacturing, licensing and distribution services and maintains R&D capabilities focused on generic product development and targeted specialty therapeutics.

Headquartered in Petah Tikva, Israel, Teva has grown through a combination of organic expansion and acquisitions and serves customers across North America, Europe, Latin America, Asia Pacific and other regions. The company is overseen by a board of directors and an executive management team responsible for global operations, regulatory compliance and commercial strategy. Teva’s strategic priorities include scaling its generic offerings, advancing selected specialty programs and pursuing operational efficiencies to support its extensive international footprint.

Key Stats

• Today's Range: $34.58 to $35.47
• 50-Day Range: $30.66 to $36.36
• 52-Week Range: $14.99 to $37.35
• Volume: 4.11 million shs
• Average Volume: 5.31 million shs
• Market Capitalization: $40.58 billion
• P/E Ratio: 26.53
• Dividend Yield: N/A
• Price Target: $41.78
• Consensus Rating: Moderate Buy

Teva Pharmaceutical Industries Stock Analysis - MarketRank™

Teva Pharmaceutical Industries scored higher than 94% of companies evaluated by MarketBeat, and ranked 28th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Teva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Teva Pharmaceutical Industries has a consensus price target of $41.78, representing about 18.4% upside from its current price of $35.29.

Amount of Analyst Coverage

Teva Pharmaceutical Industries has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 54.31%

Earnings Growth

Earnings for Teva Pharmaceutical Industries are expected to grow by 54.31% in the coming year, from $1.97 to $3.04 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Teva Pharmaceutical Industries is 26.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.49.

Price to Earnings Ratio vs. Sector

The P/E ratio of Teva Pharmaceutical Industries is 26.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.35.

Price to Earnings Growth Ratio

Teva Pharmaceutical Industries has a PEG Ratio of 4.23. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Teva Pharmaceutical Industries has a P/B Ratio of 5.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.92% of the float of Teva Pharmaceutical Industries has been sold short.

Short Interest Ratio / Days to Cover

Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 5.42.

Change versus previous month

Short interest in Teva Pharmaceutical Industries has recently decreased by 1.54%, indicating that investor sentiment is improving.

Dividend

• Score: 0.8 / 5
• Dividend Strength: N/A

Dividend Yield

Teva Pharmaceutical Industries does not currently pay a dividend.

Dividend Growth

Teva Pharmaceutical Industries does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 33.26% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.72

News Sentiment

Teva Pharmaceutical Industries has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Teva Pharmaceutical Industries this week, compared to 9 articles on an average week.

Search Interest

Only 8 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,332,989.00 in company stock.

Percentage Held by Insiders

0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.

Percentage Held by Institutions

54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:TEVA
• CIK: 818686
• Web: www.tevapharm.com
• Phone: (723) 914-8213
• Fax: 972-3923-4050
• Employees: 33,950
• Year Founded: 1901

Price Target and Rating

• Average Price Target for Teva Pharmaceutical Industries: $41.78
• High Price Target: $45.00
• Low Price Target: $40.00
• Potential Upside/Downside: +18.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.33
• Trailing P/E Ratio: 26.53
• Forward P/E Ratio: 17.91
• P/E Growth: 4.23
• Net Income: $1.41 billion
• Net Margins: 9.01%
• Pretax Margin: 7.87%
• Return on Equity: 43.53%
• Return on Assets: 8.19%

Debt

• Debt-to-Equity Ratio: 1.70
• Current Ratio: 1.01
• Quick Ratio: 0.78

Sales & Book Value

• Annual Sales: $17.26 billion
• Price / Sales: 2.35
• Cash Flow: $3.80 per share
• Price / Cash Flow: 9.29
• Book Value: $6.88 per share
• Price / Book: 5.13

Miscellaneous

• Outstanding Shares: 1,149,810,000
• Free Float: 1,143,604,000
• Market Cap: $40.58 billion
• Optionable: Optionable
• Beta: 0.86